SAN

77.78

+0.36%↑

UCB

250.3

+1.87%↑

SHL.DE

37.04

+1.37%↑

ARGX

593.6

+1.26%↑

VIE

31.9

+2.64%↑

SAN

77.78

+0.36%↑

UCB

250.3

+1.87%↑

SHL.DE

37.04

+1.37%↑

ARGX

593.6

+1.26%↑

VIE

31.9

+2.64%↑

SAN

77.78

+0.36%↑

UCB

250.3

+1.87%↑

SHL.DE

37.04

+1.37%↑

ARGX

593.6

+1.26%↑

VIE

31.9

+2.64%↑

SAN

77.78

+0.36%↑

UCB

250.3

+1.87%↑

SHL.DE

37.04

+1.37%↑

ARGX

593.6

+1.26%↑

VIE

31.9

+2.64%↑

SAN

77.78

+0.36%↑

UCB

250.3

+1.87%↑

SHL.DE

37.04

+1.37%↑

ARGX

593.6

+1.26%↑

VIE

31.9

+2.64%↑

Search

Laboratorios Farmaceuticos Rovi SA

Ouvert

SecteurSoins de santé

78.45 0.32

Résumé

Variation du prix de l'action

24h

Actuel

Min

75.8

Max

79.6

Chiffres clés

By Trading Economics

Revenu

-33M

43M

Ventes

7.9M

218M

P/E

Moyenne du Secteur

33.835

57.833

BPA

0.834

Marge bénéficiaire

19.539

Employés

1,950

EBITDA

-21M

63M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+10.65% upside

Dividendes

By Dow Jones

Prochains Résultats

7 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

107M

4.1B

Ouverture précédente

78.13

Clôture précédente

78.45

Sentiment de l'Actualité

By Acuity

13%

87%

12 / 350 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

22 mars 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

22 mars 2026, 23:50 UTC

Market Talk

LG Electronics Set to Stage Strong Earnings Rebound in 1Q -- Market Talk

22 mars 2026, 23:49 UTC

Market Talk
Principaux Événements d'Actualité

Gold Edges Lower on Prospects of Liquidity-Driven Sales -- Market Talk

22 mars 2026, 23:49 UTC

Market Talk
Principaux Événements d'Actualité

Nikkei May Fall as Concerns About Middle East Conflict Persist -- Market Talk

22 mars 2026, 23:49 UTC

Market Talk
Principaux Événements d'Actualité

Global Forex and Fixed Income Roundup: Market Talk

22 mars 2026, 23:41 UTC

Market Talk
Principaux Événements d'Actualité

Oil Edges Lower as Traders Eye Trump's Deadline to Reopen Strait of Hormuz -- Market Talk

22 mars 2026, 22:57 UTC

Acquisitions, Fusions, Rachats

Perseus Mining: Location of Aurum's Discoveries Present Potential Future Synergies

22 mars 2026, 22:56 UTC

Acquisitions, Fusions, Rachats

Perseus Mining: Aurum Share Acquisition Cost A$23.69 Million

22 mars 2026, 22:56 UTC

Acquisitions, Fusions, Rachats

Perseus Mining: Aurum's Boundiali Gold Project Located to South of Sissingue Gold Mine

22 mars 2026, 22:55 UTC

Acquisitions, Fusions, Rachats

Perseus Mining: Participated in Aurum Resources Equity Raising

22 mars 2026, 22:54 UTC

Acquisitions, Fusions, Rachats

Perseus Mining: Acquires 9.9% Interest in Aurum Resources

22 mars 2026, 22:22 UTC

Market Talk
Principaux Événements d'Actualité

After Selloff, Gold Seen Supported by Strait of Hormuz Deadline -- Market Talk

22 mars 2026, 22:06 UTC

Acquisitions, Fusions, Rachats

Synopsys Has Market Value Over $80 Billion; Major Customers Include Nvidia -- WSJ

22 mars 2026, 22:06 UTC

Acquisitions, Fusions, Rachats

Activist Elliott Builds Big Stake in Chip-Design Software Maker Synopsys -- WSJ

22 mars 2026, 22:06 UTC

Acquisitions, Fusions, Rachats

Activist Elliott Investment Management Has Multibillion-Dollar Investment in Synopsys, Sources Say -- WSJ

22 mars 2026, 22:06 UTC

Acquisitions, Fusions, Rachats

Elliott Plans to Push Synopsys to Make More Money From Its Software and Services, Sources Say -- WSJ

22 mars 2026, 21:53 UTC

Résultats

Zijin Gold International Plans 59.2 Tons of Gold Production in 2026; up 12.3% on Year >2259.HK

22 mars 2026, 21:53 UTC

Résultats

Zijin Gold International Rising Gold Prices Supported Results >2259.HK

22 mars 2026, 21:53 UTC

Résultats

Zijin Gold International 2025 Rev $5.38B Vs. $2.99B >2259.HK

22 mars 2026, 21:53 UTC

Résultats

Zijin Gold International 2025 Net $1.60B Vs. Net $481.37M >2259.HK

22 mars 2026, 21:31 UTC

Résultats

China Petroleum & Chemical Plans CNY131.6B-CNY148.6B Capex Spending in 2026>0386.HK

22 mars 2026, 21:31 UTC

Résultats

China Petroleum & Chemical: Decrease in Sales Volumes of Refined Oil Products Also Hurt Results >0386.HK

22 mars 2026, 21:31 UTC

Résultats

China Petroleum & Chemical 2025 Results Weighed by Decrease in Prices of Petroleum, Petrochemical Products>0386.HK

22 mars 2026, 21:31 UTC

Résultats

China Petroleum & Chemical 2025 Rev CNY2.78T Vs. CNY3.07T >0386.HK

22 mars 2026, 21:31 UTC

Résultats

China Petroleum & Chemical 2025 Net CNY32.48B Vs. Net CNY48.94B >0386.HK

22 mars 2026, 21:25 UTC

Market Talk
Principaux Événements d'Actualité

Bonds Decoupling From Oil Amid Longer Conflict Fears -- Market Talk

22 mars 2026, 21:22 UTC

Acquisitions, Fusions, Rachats

St Barbara: Remarks Follow Recent Inquiries About Simberi's Fuel Stocks

22 mars 2026, 21:21 UTC

Acquisitions, Fusions, Rachats

St Barbara: Simberi Currently Uses About 65,000 Liters Per Day For Mining Fleet, Power Generation

22 mars 2026, 21:21 UTC

Market Talk

Revised Fuel Subsidy Mechanism Positive for Ampol, Viva Energy -- Market Talk

22 mars 2026, 21:21 UTC

Acquisitions, Fusions, Rachats

St Barbara: Has Been Taking Precaution to Increase Diesel Storage For Several Months

Comparaison

Variation de prix

Laboratorios Farmaceuticos Rovi SA prévision

Objectif de Prix

By TipRanks

10.65% hausse

Prévisions sur 12 Mois

Moyen 86.75 EUR  10.65%

Haut 90 EUR

Bas 83.5 EUR

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

1

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

51.1 / N/ASupport & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

12 / 350Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat